AGL and type 1 diabetes mellitus: On the other hand, AGL-lipoic acid conjugate [compound 1, Figure 1, orally (p.o.)once daily for 6 days] in alloxan-treated mice (model: type 1 diabetes) was reported to lower blood glucose, increase in insulin secretion and prevention of loss of β-cells and their dysfunction, stimulating GLUT4 membrane translocation in soleus muscles.